Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

China’s NHSA Opens NRDL to AI and Digital Health Innovation, Unveils Scenario‑Driven Reimbursement Reform

Fineline Cube Feb 6, 2026
Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Fineline Cube Feb 6, 2026
Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Fineline Cube Feb 6, 2026
Company Drug

Staidson Pharmaceutical Gets FDA Clearance for TNFR2-Targeted mAb SBT-1901

Fineline Cube Jun 25, 2024

Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a biopharmaceutical company based in China, has announced...

Company Deals

Jiangsu Jibeier Pharm Completes Private Placement to Fund R&D Center on STAR Market

Fineline Cube Jun 25, 2024

Jiangsu Jibeier Pharm Co., Ltd (SHA: 688566), a Chinese pharmaceutical company, has announced the successful...

Company Drug

Hybio Pharmaceutical’s Biosimilar Liraglutide Gets Temporary FDA Nod Pending Patent Expiry

Fineline Cube Jun 25, 2024

Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese pharmaceutical company, has announced that it has...

Company Drug

Asieris Pharmaceuticals Gets NMPA Green Light for APL-1202 Clinical Trial in FLA Infections

Fineline Cube Jun 25, 2024

Asieris Pharmaceuticals (SHA: 688176), a Chinese specialist in urogenital cancer, has announced that it has...

Company Deals

Tonghua Dongbao Pharmaceuticals Partners with Sinopharm for Supply Chain and Market Expansion

Fineline Cube Jun 25, 2024

Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has entered into a strategic partnership...

Company Deals

Fosun Pharma to Take Henlius Private in Deal Valued at HKD 5.407 Billion

Fineline Cube Jun 25, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced plans to take...

Company Drug

Shanghai Haihe Pharmaceutical’s Glumetinib Earns Marketing Approval in Japan for NSCLC Treatment

Fineline Cube Jun 25, 2024

Shanghai Haihe Pharmaceutical Co., Ltd, a Chinese pharmaceutical company, has announced that it has received...

Company Deals

Sun Yat-sen University and KingMed Diagnostics Collaborate on Talent Development and Research

Fineline Cube Jun 25, 2024

On June 20, 2024, the School of Public Health (Shenzhen) of Sun Yat-sen University and...

Company Deals

AnDiConBio Secures Over RMB 200 Million in Series A Financing to Advance Respiratory and Pain Therapies

Fineline Cube Jun 25, 2024

AnDiConBio, a Zhejiang-based innovative pharmaceutical company specializing in respiratory infections and pain management, has reportedly...

Company Drug

Haisco Pharmaceutical Gets NMPA Green Light for Cofrogliptin to Treat Type 2 Diabetes

Fineline Cube Jun 25, 2024

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received marketing approval...

Company Drug

Gan & Lee Pharmaceuticals’ GZR18 Outperforms Market Similars in Weight Reduction Study

Fineline Cube Jun 25, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced the presentation of...

Company Drug

Novo Nordisk’s Once-Weekly Insulin Awiqli Approved by China’s NMPA for Type 2 Diabetes

Fineline Cube Jun 25, 2024

The National Medical Products Administration (NMPA) has granted market approval for Awiqli (insulin icodec), a...

Company Drug

Innovent Biologics’ Mazdutide Shows Promise in Phase III Obesity Trial

Fineline Cube Jun 25, 2024

Innovent Biologics Inc. (HKG: 1801), a biopharmaceutical company based in China, has announced the presentation...

Company Drug

Takeda’s Fruquintinib for Metastatic Colorectal Cancer Receives European Commission Marketing Approval

Fineline Cube Jun 24, 2024

HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its partner Takeda (TYO: 4502,...

Company Deals

ClouDr Secures Exclusive Sub-Licensing Rights for Iloprost Infusion Solution

Fineline Cube Jun 24, 2024

Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), operating under the brand name “ClouDr,”...

Legal / IP

Biocytogen Secures US Patent for RenLite Fully Human Common Light Chain Mouse Platform

Fineline Cube Jun 24, 2024

Biocytogen (HKG: 2315), a biopharmaceutical company based in China, has announced that it has been...

Company Drug

ImmuneOnco Biopharmaceuticals Receives NMPA Approval for CD47 and CD20 Dual-Targeted BsAb in SLE

Fineline Cube Jun 24, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received clinical trial...

Company Deals

Shanghai Pharmaceuticals’ Subsidiary Shaphar Med Collaborates with Magic Med to Enter Oncology

Fineline Cube Jun 24, 2024

Shanghai Pharmaceuticals Holding Co., Ltd (SPH, SHA: 601607; HKG: 2607), a leading pharmaceutical company in...

Company Drug

Sichuan Biokin Pharmaceutical Gets NMPA Go-Ahead for BL-M17D1 Solid Tumor Clinical Study

Fineline Cube Jun 24, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a pharmaceutical company based in China, has announced...

Company Drug

StarryGene Initiates Phase I Clinical Trial for XMVA09 Gene Therapy in wAMD

Fineline Cube Jun 24, 2024

StarryGene, a biotech company specializing in gene therapy and based in Hefei, China, has announced...

Posts pagination

1 … 296 297 298 … 621

Recent updates

  • Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging
  • Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China
  • Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial
  • Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China
  • Ascentage Pharma Secures NMPA Approval for APG‑3288 BTK Degrader Trial in Hematologic Malignancies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Company Drug

Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.